abstract |
Disclosed is the use of a transmembrane activator and a calcium modulator and cyclophilin ligand-interactor (TACI)-immunoglobulin fusion protein for the manufacture of a medicament for inhibiting the proliferation of tumor cells, wherein the TACI-immunoglobulin fusion protein comprises: a) a TACI receptor moiety that is a polypeptide consisting of a sequence of 32-80 amino acids in length, wherein the TACI receptor moiety comprises at least of (i) amino acid residues 34 to 66 of SEQ ID NO:2 and (ii) amino acid residues 71 to 104 of SEQ ID NO:2, and wherein the TACI receptor moiety binds at least one of ZTNF2 or ZTNF4, and b) an immunoglobulin moiety comprising a constant region of an immunoglobulin, wherein the amount of fusion protein produced is at least 2.3pg/cell/day. |